New developments in the diagnosis of dementia
- PMID: 20963198
- PMCID: PMC2957616
- DOI: 10.3238/arztebl.2010.0677
New developments in the diagnosis of dementia
Abstract
Background: The terms "dementia" and "Alzheimer's disease" are often wrongly used as if they were synonyms. Dementia is a clinical syndrome whose main element is memory impairment; it is due to Alzheimer's disease in more than 75% of cases. Alzheimer's disease, on the other hand, is a neuropathological entity that is characterized by a protracted preclinical phase followed by the onset of slowly progressive dementia.
Methods: We here review relevant literature that we retrieved by a selective Medline search (2005-2009), paying special attention to the early diagnosis of Alzheimer's disease, its clinical manifestations, and its relevance in primary care.
Results: The early clinical manifestations of a dementing illness can be detected in primary care through the use of simple screening tests such as the mini mental state examination, clock drawing tests, and DemTect. A diminished concentration of Abeta-peptide and an increase of (phospho-)tau in the cerebrospinal fluid can suggest the presence of Alzheimer's disease even before the onset of dementia: these substances are components of amyloid plaques and neurofibrillary tangles, which are the characteristic neuropathological lesions of Alzheimer's disease. New types of morphological magnetic resonsance imaging (MRI), and automated analysis of the images obtained, can improve the consistency of radiological assessment over the traditional visual method and thus enable more secure diagnosis.
Conclusion: The early, preclinical phase of Alzheimer's disease involves what has been termed mild cognitive impairment and may last as long as five years until the onset of dementia. With the aid of the new biomarkers described here, the likelihood of diagnosing Alzheimer's disease correctly in this phase can be raised above 80%. Early detection of Alzheimer's disease before the onset of dementia provides an opportunity to study potential approaches for secondary prevention, which are now an object of intense clinical research.
Figures
Comment in
-
The investigation and differential diagnosis of dementias.Dtsch Arztebl Int. 2010 Oct;107(39):675-6. doi: 10.3238/arztebl.2010.0675. Epub 2010 Oct 1. Dtsch Arztebl Int. 2010. PMID: 20963197 Free PMC article. No abstract available.
Similar articles
-
Relationship of dementia screening tests with biomarkers of Alzheimer's disease.Brain. 2010 Nov;133(11):3290-300. doi: 10.1093/brain/awq204. Epub 2010 Sep 7. Brain. 2010. PMID: 20823087 Free PMC article.
-
Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment.Acta Neurol Scand Suppl. 2003;179:47-51. doi: 10.1034/j.1600-0404.107.s179.9.x. Acta Neurol Scand Suppl. 2003. PMID: 12603251 Clinical Trial.
-
Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.Brain. 2015 Sep;138(Pt 9):2716-31. doi: 10.1093/brain/awv181. Epub 2015 Jun 30. Brain. 2015. PMID: 26133663
-
Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein.Drugs Today (Barc). 2007 Jun;43(6):423-31. doi: 10.1358/dot.2007.43.6.1067341. Drugs Today (Barc). 2007. PMID: 17612711 Review.
-
Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease.Clin Chem Lab Med. 2011 Mar;49(3):367-74. doi: 10.1515/CCLM.2011.087. Epub 2011 Feb 23. Clin Chem Lab Med. 2011. PMID: 21342022 Review.
Cited by
-
Manipulation of the diet-microbiota-brain axis in Alzheimer's disease.Front Neurosci. 2022 Nov 4;16:1042865. doi: 10.3389/fnins.2022.1042865. eCollection 2022. Front Neurosci. 2022. PMID: 36408394 Free PMC article. Review.
-
Modelling Neurological Diseases in Large Animals: Criteria for Model Selection and Clinical Assessment.Cells. 2022 Aug 25;11(17):2641. doi: 10.3390/cells11172641. Cells. 2022. PMID: 36078049 Free PMC article. Review.
-
Associations between social burden, perceived stress, and diurnal cortisol profiles in older adults: implications for cognitive aging.Eur J Ageing. 2021 Mar 28;18(4):575-590. doi: 10.1007/s10433-021-00616-8. eCollection 2021 Dec. Eur J Ageing. 2021. PMID: 34786017 Free PMC article.
-
Pharmacological Targets and the Biological Mechanisms of Formononetin for Alzheimer's Disease: A Network Analysis.Med Sci Monit. 2019 Jun 8;25:4273-4277. doi: 10.12659/MSM.916662. Med Sci Monit. 2019. PMID: 31175839 Free PMC article.
-
Diagnosis of Alzheimer's disease in Brazil: Supplementary exams.Dement Neuropsychol. 2011 Jul-Sep;5(3):167-177. doi: 10.1590/S1980-57642011DN05030004. Dement Neuropsychol. 2011. PMID: 29213741 Free PMC article. Review.
References
-
- Dementia in Europe. Yearbook 2006. Alzheimer Europe 2006. http://ec.europa.eu/health/ph_information/reporting/docs/2006_dementiaye....
-
- Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift für Psychiatrie. 1907;64:146–148.
-
- Schlachetzki JCM, Hüll M. Microglial activation in Alzheimer’s disease. Current Alzheimer Research. 2009;6:554–563. - PubMed
-
- Braak H, Braak E. Staging of Alzheimer’s disease-related neuro-fibrillary changes. Neurobiol Aging. 1995;16(3):271–278. - PubMed
-
- Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183–194. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
